HOME > MARKETS > MARKET COMMENTARY
  MARKET COMMENTARY
EQUITY
Zydus Lifesciences gains as its arm inks pact with PRG S&T to license molecule for HGPS
Mar-17-2026

Zydus Lifesciences is currently trading at Rs. 895.80, up by 9.50 points or 1.07% from its previous closing of Rs. 886.30 on the BSE.

The scrip opened at Rs. 898.95 and has touched a high and low of Rs. 902.00 and Rs. 891.15 respectively. So far 4336 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1059.00 on 19-Sep-2025 and a 52 week low of Rs. 797.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 936.00 and Rs. 853.05 respectively. The current market cap of the company is Rs. 90520.81 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 18.15% and 6.85% respectively.

Zydus Lifesciences’ wholly-owned subsidiary -- Sentynl Therapeutics Inc. (Sentynl), a U.S.-based biopharmaceutical company, has entered into an agreement with PRG S&T, a Korean company specializing in the development of medicine for rare genetic diseases, to license its investigational molecule Progerinin (SLC-D011) for Hutchinson-Gilford Progeria Syndrome (HGPS or progeria).

The agreement will allow Sentynl to begin working with PRG S&T immediately to advance the clinical development of Progerinin for HGPS, which has been designated as an orphan drug by the United States Food and Drug Administration (FDA). Under the conditions that certain steps are met, Sentynl will acquire full rights to the molecule for HGPS upon closing, making Progerinin the company’s second therapy intended for the treatment of HGPS. The program is currently finalizing a Phase 2A clinical trial and data are expected before the end of 1H 2026.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

  RELATED NEWS >>